United Therapeutics Corporation (NASDAQ:UTHR) Shares Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 37.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,600 shares of the biotechnology company's stock after buying an additional 16,300 shares during the period. KLP Kapitalforvaltning AS owned 0.13% of United Therapeutics worth $18,373,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Avantax Advisory Services Inc. purchased a new stake in shares of United Therapeutics in the fourth quarter valued at $209,000. Commonwealth Equity Services LLC grew its position in shares of United Therapeutics by 3.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 8,526 shares of the biotechnology company's stock valued at $3,008,000 after purchasing an additional 301 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in shares of United Therapeutics by 8.1% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,082 shares of the biotechnology company's stock valued at $382,000 after purchasing an additional 81 shares during the period. Fox Run Management L.L.C. acquired a new position in United Therapeutics in the fourth quarter valued at $429,000. Finally, LPL Financial LLC boosted its holdings in United Therapeutics by 122.8% in the fourth quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock valued at $5,024,000 after acquiring an additional 7,847 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total value of $3,345,210.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at $11,185,469.91. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock valued at $24,628,589 in the last three months. Corporate insiders own 10.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Bank of America reduced their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Trading Down 0.6%

United Therapeutics stock traded down $1.91 during midday trading on Friday, hitting $304.50. The stock had a trading volume of 310,921 shares, compared to its average volume of 372,488. The stock has a market cap of $13.74 billion, a P/E ratio of 12.15, a P/E/G ratio of 6.64 and a beta of 0.53. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The business has a fifty day moving average price of $300.01 and a 200 day moving average price of $315.85.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. United Therapeutics's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the company earned $6.17 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.